SCHEDULE 13G/A: BlackRock Discloses 6.1% Stake in Relay Therapeutics

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.1% beneficial ownership stake in Relay Therapeutics, Inc. as of March 31, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 10,308,012 shares of Relay Therapeutics, Inc. common stock.
• This aggregate amount represents 6.1% of the total outstanding common shares of Relay Therapeutics, Inc.
• The filing is an Amendment No. 4 to Schedule 13G, indicating an update to previous ownership disclosures.
• BlackRock holds sole voting power over 10,102,938 shares and sole dispositive power over 10,308,012 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Relay Therapeutics, Inc.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of a significant institutional ownership stake, indicating a stable, passive investment by BlackRock. It contains no negative information about the issuer, Relay Therapeutics, Inc., but also no specific positive news beyond the fact of the investment itself.

Positives

• The disclosure of a significant stake by a major institutional investor like BlackRock can signal confidence in the company's long-term prospects.
• The filing explicitly states that BlackRock holds the shares in the ordinary course of business and not for activist purposes, suggesting a stable, passive investment.

Negatives

• The document itself does not contain any negative information regarding Relay Therapeutics, Inc.

Risks

• The document does not explicitly detail risks related to Relay Therapeutics, Inc.

Future Outlook

NA

Management Comments

• "In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the 'Reporting Business Units') of BlackRock, Inc. and its subsidiaries and affiliates."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

This filing is a standard disclosure of a significant institutional investment, common across various industries. It reflects BlackRock's ongoing portfolio management activities and its position as a major passive investor in publicly traded companies.

Corporate Governance

Stakeholder Impact

• Shareholders: The disclosure of a large institutional holder like BlackRock can provide a sense of stability and validation for the company's stock.
• Management: Awareness of a significant passive investor on the shareholder register.

Key Dates

Keywords

BlackRock, Relay Therapeutics, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Ownership Disclosure, SEC Filing, RLAY